- Home
- CIA vs PROK Comparison
CIA vs PROK Comparison
Compare CIA & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIA
- PROK
- Stock Information
- Founded
- CIA 1969
- PROK 2015
- Country
- CIA United States
- PROK United States
- Employees
- CIA N/A
- PROK N/A
- Industry
- CIA Life Insurance
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIA Finance
- PROK Health Care
- Exchange
- CIA Nasdaq
- PROK Nasdaq
- Market Cap
- CIA 230.6M
- PROK 206.0M
- IPO Year
- CIA N/A
- PROK N/A
- Fundamental
- Price
- CIA $5.18
- PROK $1.50
- Analyst Decision
- CIA
- PROK Buy
- Analyst Count
- CIA 0
- PROK 5
- Target Price
- CIA N/A
- PROK $4.50
- AVG Volume (30 Days)
- CIA 122.6K
- PROK 344.0K
- Earning Date
- CIA 03-13-2025
- PROK 03-21-2025
- Dividend Yield
- CIA N/A
- PROK N/A
- EPS Growth
- CIA N/A
- PROK N/A
- EPS
- CIA 0.43
- PROK N/A
- Revenue
- CIA $248,376,000.00
- PROK N/A
- Revenue This Year
- CIA N/A
- PROK N/A
- Revenue Next Year
- CIA $3.85
- PROK N/A
- P/E Ratio
- CIA $11.98
- PROK N/A
- Revenue Growth
- CIA 3.02
- PROK N/A
- 52 Week Low
- CIA $1.78
- PROK $1.34
- 52 Week High
- CIA $5.95
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- CIA 53.85
- PROK 41.47
- Support Level
- CIA $5.17
- PROK $1.50
- Resistance Level
- CIA $5.56
- PROK $1.67
- Average True Range (ATR)
- CIA 0.33
- PROK 0.10
- MACD
- CIA -0.04
- PROK -0.00
- Stochastic Oscillator
- CIA 44.90
- PROK 10.71
About CIA Citizens Inc. ($1.00 Par)
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. the Company derives its revenues principally from life insurance premiums earned for insurance coverages provided to insureds in our two operating segments and net investment income. The company operates in two business segments namely the Life Insurance segment and the Home Service Insurance segment. The company majority generates revenues from Life Insurance segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.